VanEck Associates
GH icon

VanEck Associates’s Guardant Health GH Stock Holding History

VanEck Associates’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Sell
3,559
-3,260
-48% -$355K ﹤0.01% 1224
2026
Q1 		$630K Sell
6,819
-315
-4% -$31.6K ﹤0.01% 1151
2025
Q4 		$729K Buy
7,134
+3,503
+96% +$313K ﹤0.01% 1120
2025
Q3 		$227K Buy
3,631
+799
+28% +$43.5K ﹤0.01% 1273
2025
Q2 		$147K Buy
2,832
+448
+19% +$20K ﹤0.01% 1277
2025
Q1 		$102K Sell
2,384
-503
-17% -$21.7K ﹤0.01% 1278
2024
Q4 		$88K Buy
2,887
+929
+47% +$26.1K ﹤0.01% 1277
2024
Q3 		$40K Sell
1,958
-897
-31% -$25.4K ﹤0.01% 1282
2024
Q2 		$82K Sell
2,855
-83
-3% -$1.93K ﹤0.01% 1263
2024
Q1 		$61K Buy
2,938
+236
+9% +$5.06K ﹤0.01% 1269
2023
Q4 		$73K Buy
2,702
+614
+29% +$16.1K ﹤0.01% 1266
2023
Q3 		$62K Buy
2,088
+187
+10% +$6.58K ﹤0.01% 1264
2023
Q2 		$68K Buy
1,901
+254
+15% +$7.29K ﹤0.01% 1280
2023
Q1 		$39K Sell
1,647
-83,518
-98% -$2.39M ﹤0.01% 1319
2022
Q4 		$2.32M Buy
85,165
+12,973
+18% +$594K 0.01% 648
2022
Q3 		$3.89M Sell
72,192
-26,851
-27% -$1.38M 0.01% 486
2022
Q2 		$4M Buy
99,043
+1,743
+2% +$86.4K 0.01% 514
2022
Q1 		$6.45M Sell
97,300
-29,217
-23% -$2M 0.01% 454
2021
Q4 		$12.7M Sell
126,517
-5,173
-4% -$535K 0.03% 327
2021
Q3 		$16.5M Sell
131,690
-24,942
-16% -$2.96M 0.04% 274
2021
Q2 		$19.5M Buy
156,632
+8,331
+6% +$1.12M 0.05% 254
2021
Q1 		$22.6M Buy
148,301
+2,636
+2% +$398K 0.06% 212
2020
Q4 		$18.8M Buy
145,665
+7,792
+6% +$897K 0.05% 214
2020
Q3 		$15.4M Buy
137,873
+1,399
+1% +$128K 0.05% 211
2020
Q2 		$11.1M Buy
136,474
+46,031
+51% +$3.71M 0.04% 242
2020
Q1 		$6.29M Sell
90,443
-8,184
-8% -$628K 0.03% 279
2019
Q4 		$7.71M Buy
98,627
+11,156
+13% +$804K 0.03% 301
2019
Q3 		$5.58M Buy
+87,471
New +$7.71M 0.03% 323

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

VanEck Associates's GH Position: Q2 2026 in Review

VanEck Associates reduced its Guardant Health (GH) stake by 48% in Q2 2026, selling an estimated $355K and leaving 3,559 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #1224.

VanEck Associates first reported a position in GH in Q3 2019 and has held it in 28 quarters since. The position peaked at $22.6M in Q1 2021. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • VanEck Associates held 3,559 shares of Guardant Health worth $534K as of Q2 2026.
  • VanEck Associates sold 3,260 Guardant Health shares in Q2 2026, an estimated $355K.
  • Guardant Health made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #1224 holding.
  • VanEck Associates first reported a position in Guardant Health in Q3 2019 and has held it in 28 quarters since.
  • VanEck Associates's Guardant Health position peaked at $22.6M in Q1 2021.
  • 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.